JOURNAL OF KAOHSIUNG MEDICAL ASSOCIATION 2014. vol. 22, No.

100

(NEJM)

[1]

NEJM

Journal of the American Medical

Association (JAMA)

[2]

FDA

[3]FDA

1.

100

2.

3.

(Hydroxyethyl Starch;HES)

90

371

4.

European

Medicines Agency's (EMA's)

Pharmacovigilance

Risk Assessment Committee (PRAC)

HES

[4]

NEJMTetraspan

130/0.42[5]
Voluven130/0.4

[1]NEJM

HES

HES 200/0.5

HES

[6]

FDA

372

 JOURNAL OF KAOHSIUNG MEDICAL ASSOCIATION 2014. vol. 22, No.4

4. Committee TEMAsPRA: PRAC

recommends suspending marketing

1.Myburgh JA, Finfer S, Bellomo R,

authorisations for infusion

Billot L, Cass A, Gattas D, Glass

solutions containing hydroxyethyl

P, Lipman J, Liu B, McArthur C et

starch. http://wwwemaeuropaeu/

al: Hydroxyethyl Starch or Saline

ema/indexjsp?curl=pages/news_

for Fluid Resuscitation in Intensive

and_events/news/2013/06/news_d

Care. New England Journal of

etail_001814jsp&mid=WC0b01ac

Medicine, 367(20):1901-1911.

058004d5c1.

2.Zarychanski R A-SAMTAF, et al.:

5.Perner A, Haase N, Guttormsen

Association of hydroxyethyl starch

AB, Tenhunen J, Klemenzson G,

administration with mortality and

?neman A, Madsen KR, Mller

acute kidney injury in critically

MH, Elkjr JM, Poulsen LM et

ill patients requiring volume

al: Hydroxyethyl Starch 130/0.42

resuscitation: A systematic

versus Ringer's Acetate in Severe

review and meta-analysis. JAMA,

Sepsis. New England Journal of

309(7):678-688.

Medicine, 367(2):124-134.

3.FDA: Hydroxyethyl Starch

6.Brunkhorst FM, Engel C, Bloos F,

Solutions: FDA Safety

Meier-Hellmann A, Ragaller M,

Communication - Boxed Warning

Weiler N, Moerer O, Gruendling

on Increased Mortality and Severe

M, Oppert M, Grond S et al:

Renal Injury and Risk of Bleeding.

Intensive Insulin Therapy and

h t t p : / / w w w. f d a . g o v / S a f e t y /

Pentastarch Resuscitation in Severe

MedWatch/SafetyInformation/Safe

Sepsis. New England Journal of

tyAlertsforHumanMedicalProduct

Medicine 2008, 358(2):125-139.

s/ucm358349.htm.

373